The impact of admission procalcitonin on prognosis in acute coronary syndromes: A pilot study

Claudio Picariello, Chiara Lazzeri, Paola Attan, Marco Chiostri, Gian Franco Gensini, Serafina Valente

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Available evidence on the prognostic role of procalcitonin levels in acute coronary syndromes (ACS) is so far controversial. Aims: To evaluate the association between procalcitonin, major cardiovascular events (MACE) and total mortality in acute coronary syndromes. Methods: Procalcitonin levels were measured in 247 patients admitted to our Intensive Cardiac Care Unit (ICCU) with ACS. Three subgroups were considered according to procalcitonin levels. Results: At Cox regression analysis, procalcitonin levels were both an unadjusted and an adjusted predictor (corrected for diagnosis and TnI) of intra-ICCU mortality and of 1-year follow-up MACE and total mortality. Conclusions: In ACS, admission procalcitonin values identify a "higher risk" group of patients for short and long-term mortality.

Original languageEnglish
Pages (from-to)56-61
Number of pages6
JournalBiomarkers
Volume17
Issue number1
DOIs
Publication statusPublished - Feb 2012

Keywords

  • Acute coronary syndromes
  • Cardiogenic shock
  • Mortality
  • Procalcitonin
  • Prognosis

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Fingerprint

Dive into the research topics of 'The impact of admission procalcitonin on prognosis in acute coronary syndromes: A pilot study'. Together they form a unique fingerprint.

Cite this